JANUARY 16, 2017

Fedora Pharmaceuticals Receives Support from the Government of Canada to Battle Antimicrobial Resistance with Novel Pipeline of Antibiotic Candidates

 

JANUARY, 2016

Fedora co-signs the  Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance

 

 

NOVEMBER 30, 2015

Fedora Pharmaceuticals Receives Alberta Life Sciences "Company of the Year" Award

 

 

Board of Directors

Christopher G. Micetich, Director

President and CEO, Fedora Pharmaceuticals

 

Mr. Micetich founded Fedora in 2012 after in-licensing a family of beta-lactamase inhibitors. Under Mr. Micetich’s leadership, these beta-lactamase inhibitors underwent optimization and preclinical development, after which they were licensed to Roche in January 2015 in a deal worth up to $750 million.

 

Earlier, Mr. Micetich was the chief operating officer at SynPhar Laboratories Inc., a joint venture with Taiho Pharmaceuticals Inc. dedicated to early drug discovery in the area of infectious diseases. At SynPhar, he was responsible for all aspects of administration including business development, international affairs and strategic planning, playing an instrumental role in building the operation to 65 full-time permanent employees. In 1998, Mr. Micetich founded an independent contract chemistry company called DrisCorp Inc. that performed early stage lead optimization, process development and custom synthesis.

 

In 1999, Mr. Micetich co-orchestrated an acquisition of all assets of SynPhar from their majority Japanese partner, Taiho, which were merged into NAEJA Pharmaceutical Inc., a newly created, privately controlled company. In October of that year, he merged DrisCorp into NAEJA, a contract research organization with a specialty in infectious diseases.

 

In addition to his career in specialty pharmaceuticals, Mr. Micetich founded Windjammer Java Roasters Inc., a specialty coffee roasting company and Brass Dome Ventures Ltd., a management and business consultancy.

 

Mr. Micetich graduated from the University of Alberta in 1986.

 

 

Ronald Odynski, Chairman

Managing Partner, Ogilvie LLP

 

Mr. Odynski currently serves as the managing partner of Ogilvie LLP and provides general counsel legal support and corporate governance advice for a variety of private and public sector organizations. He currently serves on the Boards of Directors of Serenic Corporation and the Alberta Ballet Company. At Ogilvie, his practice areas include health care, research and advanced technology. Within healthcare specifically, Mr. Odynski has advised Alberta Innovates - Health Solutions as well as its predecessor, the Alberta Heritage Foundation for Medical Research. He served the Kidney Foundation of Canada as Alberta president, national vice president and member of the National Medical Advisory Committee and in 1979 was a recipient of the National President’s Award, which is granted to individuals or groups demonstrating outstanding contribution and dedication to the Kidney Foundation. Further, he served as general legal counsel and a founding Board member at Synphar Laboratories Inc., a biopharmaceutical company founded by the late Dr. Ronald Micetich, from 1987 to 1999. Mr. Odynski received his Bachelor of Arts and Bachelor of Laws from the University of Alberta. At the Alberta School of Business, he was granted the Institute of Corporate Directors ICD.D designation.

 

 

Dr. Leonard E. Post, Director

Chief Scientific Officer, BioMarin Pharmaceuticals

 

Dr. Post has over 30 years of experience in all stages of pharmaceutical and biotechnology company R&D from early drug discovery through clinical development and FDA approval. Dr. Post is currently the chief scientific officer of BioMarin Pharmaceuticals, a publicly traded biopharmaceuticals company with four marketed products and five currently in clinical development. In addition, he sits on the Boards of Directors of Altiris Therapeutics and Orphagen Pharmaceuticals, two private biotechnology companies and Viralytics, a public biotechnology company listed on the Australian Stock Exchange. Prior to joining BioMarin, Dr. Post held various senior research positions at LEAD Therapeutics, Onyx Pharmaceuticals and Parke-Davis Pharmaceuticals. He received a Bachelor of Science in chemistry from the University of Michigan and a doctorate in biochemistry from the University of Wisconsin, after which he performed a postdoctoral fellowship in virology at the University of Chicago with Dr. Bernard Roizman.